MITOCARE: TRO40303 intravenous infusion in the context of primary angioplasty

Prospective, multicenter, randomized, double-blind study evaluated intravenous infusion of TRO40303 versus placebo administered immediately before balloon dilation of the culprit artery during primary angioplasty. Infarct size was evaluated using the CK Mb levels and troponin together with magnetic resonance imaging. 163 patients were included; no significant differences were observed in the area under the curve of myocardial necrosis markers at 3 days after infarction. Neither difference in terms of a smaller infarct size with MRI was observed. 

9_dan_atar
Dan Atar
2014-09-01

Original title: Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: Results of the MITOCARE study.

More articles by this author

NONI: Inhaled nitric oxide to reduce reperfusion injury in myocardial infarction

Infarct size is an independent predictor of survival and ventricular function. Several alternatives have been tried to reduce the size of the infarcted area...

ATLANTIC: administration of ticagrelor in the ambulance versus in the cath lab

The platelet P2Y12 receptor antagonist ticagrelor is shown to reduce the incidence of cardiovascular events when administered in hospital admission to patients suffering an...

FAMOUS NSTEMI: FFR versus Angiography in non-ST segment elevation myocardial infarction

The benefit of myocardial revascularization (angioplasty or surgery) guided by fractional flow reserve (FFR) in the context of acute coronary syndromes is poorly studied...

CULPRIT: Complete revascularization versus culprit artery of infarct only

Current guidelines suggest treating only the culprit artery of myocardial infarction with ST-segment elevation. This prospective and randomized work included 296 patients in 7...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long-Term Predictors of Valve Deterioration After TAVI

Transcatheter aortic valve implantation (TAVI) has become an innovative technology for the treatment of patients with severe aortic valve stenosis. Initially implemented in elderly...

Coronary access after TAVI with fourth- and fifth-generation Evolut valves: the EPROMPT-CA study

The expansion of transcatheter aortic valve implantation (TAVI) toward younger and lower-risk patients has increased the relevance of post-procedural coronary access. In this context,...

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...